Malouf Reem, Grimley Evans John
Department of Psychiatry, Oxfordshire and Buckinghamshire Mental Health Trust, John Radcliffe Hospital (4th Floor, Room 4401C), Headington, Oxford, UK, OX3 9DU.
Cochrane Database Syst Rev. 2008 Oct 8(4):CD004514. doi: 10.1002/14651858.CD004514.pub2.
Folate deficiency can result in congenital neural tube defects and megaloblastic anaemia. Low folate levels may be due to insufficient dietary intake or inefficient absorption, but impaired metabolic utilization also occurs.Because B12 deficiency can produce a similar anaemia to folate deficiency, there is a risk that folate supplementation can delay the diagnosis of B12 deficiency, which can cause irreversible neurological damage. Folic acid supplements may sometimes therefore include vitamin B12 supplements with simultaneous administration of vitamin B12.Lesser degrees of folate inadequacy are associated with high blood levels of the amino acid homocysteine which has been linked with the risk of arterial disease, dementia and Alzheimer's disease. There is therefore interest in whether dietary supplementation can improve cognitive function in the elderly.However, any apparent benefit from folic acid which was given in combination with B12 needs to be "corrected" for any effect of vitamin B12 alone. A separate Cochrane review of vitamin B12 and cognitive function has therefore been published.
To examine the effects of folic acid supplementation, with or without vitamin B12, on elderly healthy or demented people, in preventing cognitive impairment or retarding its progress.
Trials were identified from a search of the Cochrane Dementia and Cognitive Improvement Group's Specialized Register on 10 October 2007 using the terms: folic acid, folate, vitamin B9, leucovorin, methyltetrahydrofolate, vitamin B12, cobalamin and cyanocobalamin. This Register contains references from all major health care databases and many ongoing trials databases. In addition MEDLINE, EMBASE, CINAHL, PsychINFO and LILACS were searched (years 2003-2007) for additional trials of folate with or without vitamin B12 on healthy elderly people.
All double-blind, placebo-controlled, randomized trials, in which supplements of folic acid with or without vitamin B12 were compared with placebo for elderly healthy people or people with any type of dementia or cognitive impairment.
The reviewers independently applied the selection criteria and assessed study quality. One reviewer extracted and analysed the data. In comparing intervention with placebo, weighted mean differences and standardized mean difference or odds ratios were estimated.
Eight randomized controlled trials fulfilled the inclusion criteria for this review. Four trials enrolled healthy older people, and four recruited participants with mild to moderate cognitive impairment or dementia with or without diagnosed folate deficiency. Pooling the data was not possible owing to heterogeneity in sample selections, outcomes, trial duration, and dosage. Two studies involved a combination of folic acid and vitamin B12.There is no adequate evidence of benefit from folic acid supplementation with or without vitamin B12 on cognitive function and mood of unselected healthy elderly people. However, in one trial enrolling a selected group of healthy elderly people with high homocysteine levels, 800 mcg/day folic acid supplementation over three years was associated with significant benefit in terms of global functioning (WMD 0.05, 95% CI 0.004 to 0.096, P = 0.033); memory storage (WMD 0.14, 95% CI 0.04 to 0.24, P = 0.006) and information-processing speed (WMD 0.09, 95% CI 0.02 to 0.16, P = 0.016).Four trials involved people with cognitive impairment. In one pilot trial enrolling people with Alzheimer's disease, the overall response to cholinesterase inhibitors significantly improved with folic acid at a dose of 1mg/day (odds ratio: 4.06, 95% CI 1.22 to 13.53; P = 0.02) and there was a significant improvement in scores on the Instrumental Activities of Daily Living and the Social Behaviour subscale of the Nurse's Observation Scale for Geriatric Patients (WMD 4.01, 95% CI 0.50 to 7.52, P = 0.02). Other trials involving people with cognitive impairment did not show any benefit in measures of cognitive function from folic acid, with or without vitamin B12.Folic acid plus vitamin B12 was effective in reducing serum homocysteine concentrations (WMD -5.90, 95% CI -8.43 to -3.37, P < 0.00001). Folic acid was well tolerated and no adverse effects were reported.
AUTHORS' CONCLUSIONS: The small number of studies which have been done provide no consistent evidence either way that folic acid, with or without vitamin B12, has a beneficial effect on cognitive function of unselected healthy or cognitively impaired older people. In a preliminary study, folic acid was associated with improvement in the response of people with Alzheimer's disease to cholinesterase inhibitors. In another, long-term use appeared to improve the cognitive function of healthy older people with high homocysteine levels. More studies are needed on this important issue.
叶酸缺乏可导致先天性神经管缺陷和巨幼细胞贫血。叶酸水平低可能是由于饮食摄入不足或吸收效率低下,但代谢利用受损也会出现这种情况。由于维生素B12缺乏可导致与叶酸缺乏相似的贫血,因此存在叶酸补充剂会延迟维生素B12缺乏症诊断的风险,而这可能会导致不可逆转的神经损伤。因此,叶酸补充剂有时可能会同时包含维生素B12补充剂。叶酸轻度不足与血液中高浓度的氨基酸同型半胱氨酸有关,而同型半胱氨酸已被认为与动脉疾病、痴呆和阿尔茨海默病的风险相关。因此,人们对饮食补充剂能否改善老年人的认知功能很感兴趣。然而,叶酸与维生素B12联合使用所产生的任何明显益处都需要针对维生素B12单独产生的任何效果进行“校正”。因此,已发表了一篇关于维生素B12与认知功能的Cochrane系统评价。
研究补充叶酸(无论是否添加维生素B12)对健康或患有痴呆的老年人预防认知障碍或延缓其进展的效果。
通过检索Cochrane痴呆与认知改善小组专门注册库确定试验,检索时间为2007年10月10日,检索词为:叶酸、维生素B9、亚叶酸钙、甲基四氢叶酸、维生素B12、钴胺素和氰钴胺素。该注册库包含来自所有主要医疗保健数据库和许多正在进行的试验数据库的参考文献。此外,还检索了MEDLINE、EMBASE、CINAHL、PsychINFO和LILACS(2003年至2007年),以查找关于补充叶酸(无论是否添加维生素B12)对健康老年人影响的其他试验。
所有双盲、安慰剂对照、随机试验,其中将补充叶酸(无论是否添加维生素B12)与安慰剂用于健康老年人或患有任何类型痴呆或认知障碍的人群进行比较。
评价者独立应用入选标准并评估研究质量。由一名评价者提取和分析数据。在比较干预措施与安慰剂时,估计加权平均差、标准化平均差或比值比。
八项随机对照试验符合本综述的纳入标准。四项试验纳入了健康的老年人,四项试验招募了患有轻度至中度认知障碍或痴呆且无论是否诊断出叶酸缺乏的参与者。由于样本选择、结局、试验持续时间和剂量存在异质性,无法合并数据。两项研究涉及叶酸与维生素B12的联合使用。没有充分证据表明补充叶酸(无论是否添加维生素B12)对未选择的健康老年人的认知功能和情绪有益。然而,在一项纳入一组同型半胱氨酸水平高的选定健康老年人的试验中,三年中每天补充800微克叶酸与整体功能(加权平均差0.05,95%可信区间0.004至0.096,P = 0.033)、记忆储存(加权平均差0.14,95%可信区间0.04至0.24,P = 0.006)和信息处理速度(加权平均差0.09,95%可信区间0.02至0.16,P = 0.016)方面的显著益处相关。四项试验涉及认知障碍患者。在一项纳入阿尔茨海默病患者的试点试验中,每天服用1毫克叶酸可使对胆碱酯酶抑制剂的总体反应显著改善(比值比:4.06,95%可信区间1.22至13.53;P = 0.02),并且在日常生活活动能力量表和老年患者护士观察量表的社会行为子量表上的得分有显著改善(加权平均差4.01,95%可信区间0.50至7.52,P = 0.02)。其他涉及认知障碍患者的试验未显示补充叶酸(无论是否添加维生素B12)在认知功能测量方面有任何益处。叶酸加维生素B12可有效降低血清同型半胱氨酸浓度(加权平均差-5.90,95%可信区间-8.43至-3.37,P < 0.00001)。叶酸耐受性良好,未报告不良反应。
已完成的少量研究均未提供一致证据表明补充叶酸(无论是否添加维生素B12)对未选择的健康或认知受损老年人的认知功能有有益影响。在一项初步研究中,叶酸与阿尔茨海默病患者对胆碱酯酶抑制剂反应的改善有关。在另一项研究中,长期使用似乎可改善同型半胱氨酸水平高的健康老年人的认知功能。关于这个重要问题需要更多研究。